March 30, 2021: Health Canada has just approved BRAFTOVI (encorafenib) to be used in combination with MEKTOVI (binimetinib), for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Click HERE to read more
We hope that every province and territory will take swift steps to list this drug on their public formularies in order to make this therapy available to patients.
Save Your Skin Foundation is pleased to have submitted patient feedback on the targeted therapy Braftovi™ in combination with Mektovi®, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation. SYSF also supported Health Care Providers with their Clinician Input submissions for this treatment.
Great news for Squamous Cell Carcinoma patients! Updates:
August 2021: All provinces have listed with the exception of P.E.I. and Newfoundland & Labrador
February 3, 2021: LibtayoTM Funded in Ontario and British Columbia
December 15, 2020: LibtayoTM Funded in Quebec
December 1, 2020: LibtayoTM Funded in Manitoba and Saskatchewan
Save Your Skin Foundation Applauds the pan-Canadian Oncology Drug Review recommendation for Provincial Reimbursement of LibtayoTM for the treatment of Advanced Cutaneous Squamous Cell Carcinoma (cSCC) TORONTO, ONTARIO, January 15, 2020 – Read More
An up-to-date list of available treatments can be found on the Canadian Agency for Drugs and Technologies in Health (CADTH) website’s Provincial drug formulary database, which can be accessed HERE, and for Quebec, at the INESSS site, HERE.
Share and chat with other patients, family members and others concerned about melanoma and skin cancer through one of our social media channels